Apilimod mesylateCAS# 870087-36-8 |
- Tubastatin A
Catalog No.:BCC2158
CAS No.:1252003-15-8
- Rocilinostat (ACY-1215)
Catalog No.:BCC2144
CAS No.:1316214-52-4
- RGFP966
Catalog No.:BCC3991
CAS No.:1357389-11-7
- M344
Catalog No.:BCC2162
CAS No.:251456-60-7
- Scriptaid
Catalog No.:BCC2163
CAS No.:287383-59-9
- Tubacin
Catalog No.:BCC2428
CAS No.:537049-40-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 870087-36-8 | SDF | Download SDF |
PubChem ID | 11527330 | Appearance | Powder |
Formula | C25H34N6O8S2 | M.Wt | 610.7 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
Chemical Name | methanesulfonic acid;N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine | ||
SMILES | CC1=CC=CC(=C1)C=NNC2=NC(=NC(=C2)N3CCOCC3)OCCC4=CC=CC=N4.CS(=O)(=O)O.CS(=O)(=O)O | ||
Standard InChIKey | GAJWNIKZLYZYSY-OKUPSQOASA-N | ||
Standard InChI | InChI=1S/C23H26N6O2.2CH4O3S/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20;2*1-5(2,3)4/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28);2*1H3,(H,2,3,4)/b25-17+;; | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Apilimod mesylate Dilution Calculator
Apilimod mesylate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6375 mL | 8.1873 mL | 16.3747 mL | 32.7493 mL | 40.9366 mL |
5 mM | 0.3275 mL | 1.6375 mL | 3.2749 mL | 6.5499 mL | 8.1873 mL |
10 mM | 0.1637 mL | 0.8187 mL | 1.6375 mL | 3.2749 mL | 4.0937 mL |
50 mM | 0.0327 mL | 0.1637 mL | 0.3275 mL | 0.655 mL | 0.8187 mL |
100 mM | 0.0164 mL | 0.0819 mL | 0.1637 mL | 0.3275 mL | 0.4094 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Tozadenant
Catalog No.:BCC2011
CAS No.:870070-55-6
- A 839977
Catalog No.:BCC4290
CAS No.:870061-27-1
- xylitol pentacetate
Catalog No.:BCN6267
CAS No.:13437-68-8
- Inositol
Catalog No.:BCN8471
CAS No.:87-89-8
- D-Mannitol busulfan
Catalog No.:BCN3789
CAS No.:1187-00-4
- Tartaric acid
Catalog No.:BCN3824
CAS No.:87-69-4
- Pyrogallol
Catalog No.:BCN4424
CAS No.:87-66-1
- Gramine
Catalog No.:BCN4959
CAS No.:87-52-5
- trans-Caryophyllene
Catalog No.:BCN2644
CAS No.:87-44-5
- Isosorbide dinitrate
Catalog No.:BCC9004
CAS No.:87-33-2
- Ac-DL-Trp-OH
Catalog No.:BCC3119
CAS No.:87-32-1
- Salicylanilide
Catalog No.:BCC4712
CAS No.:87-17-2
- Acalisib (GS-9820)
Catalog No.:BCC6384
CAS No.:870281-34-8
- CAL-101 (Idelalisib, GS-1101)
Catalog No.:BCC1270
CAS No.:870281-82-6
- 3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid
Catalog No.:BCN1322
CAS No.:870456-88-5
- Bis-5,5-nortrachelogenin
Catalog No.:BCN6516
CAS No.:870480-56-1
- GW2580
Catalog No.:BCC1096
CAS No.:870483-87-7
- Ritanserin
Catalog No.:BCC7214
CAS No.:87051-43-2
- Zeylasteral
Catalog No.:BCN3065
CAS No.:87064-16-2
- Euphohelioscopin A
Catalog No.:BCN6501
CAS No.:87064-61-7
- PAP-1
Catalog No.:BCC1836
CAS No.:870653-45-5
- AC 261066
Catalog No.:BCC7848
CAS No.:870773-76-5
- Leptomycin B
Catalog No.:BCC7223
CAS No.:87081-35-4
- MK 0893
Catalog No.:BCC1752
CAS No.:870823-12-4
Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.[Pubmed:22170479]
Arthritis Rheum. 2012 Jun;64(6):1750-5.
OBJECTIVE: To investigate the safety, tolerability, pharmacokinetics, and efficacy of Apilimod mesylate, an oral interleukin-12 (IL-12)/IL-23 inhibitor, in patients with rheumatoid arthritis (RA). METHODS: We performed a phase IIa, randomized, double-blind, placebo-controlled proof-of-concept study of apilimod, in combination with methotrexate, in 29 patients with active RA (3:1 ratio of apilimod-treated to placebo-treated patients) in 3 stages. Patients received apilimod 100 mg/day or placebo for 4 weeks (stage 1) or 8 weeks (stage 2). In stage 3, patients received apilimod 100 mg twice a day or placebo for 8 weeks, with an optional extension of 4 weeks. Clinical response (Disease Activity Score in 28 joints [DAS28] and American College of Rheumatology [ACR] criteria) was assessed throughout; synovial tissue samples collected at baseline and on day 29 (stages 1 and 2) or day 57 (stage 3) were stained for cellular markers and cytokines for immunohistochemistry analysis. RESULTS: While only mild adverse events were observed in stages 1 and 2, in stage 3, all patients experienced headache and/or nausea. Among apilimod-treated patients (100 mg/day), there was a small, but significant, reduction in the DAS28 on day 29 and day 57 compared with baseline. ACR20 response was reached in only 6% of patients on day 29 and 25% of patients on day 57, similar to the percentage of responders in the placebo group. Increasing the dosage (100 mg twice a day) did not improve clinical efficacy. Consistent with clinical results, apilimod did not have an effect on expression of synovial biomarkers. Of importance, we also did not observe an effect of apilimod on synovial IL-12 and IL-23 expression. CONCLUSION: Our results do not support the notion that IL-12/IL-23 inhibition by apilimod is able to induce robust clinical improvement in RA.
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.[Pubmed:19918967]
Inflamm Bowel Dis. 2010 Jul;16(7):1209-18.
BACKGROUND: Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory cytokines linked to the Th-1 and Th-17 phenotypes associated with Crohn's disease (CD). We investigated the activity and safety of Apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with active CD. METHODS: We performed a multicenter, Phase 2, randomized, double-blinded, placebo-controlled study to evaluate the efficacy of Apilimod mesylate in treating 220 adult patients with moderate-to-severe CD (Crohn's Disease Activity Index [CDAI] score 220-450). Patients were stratified according to C-reactive protein (CRP) levels and corticosteroid use and were randomly assigned to receive placebo or Apilimod mesylate 50 mg daily or 100 mg daily. The study was divided into an induction phase (43 days) and a maintenance phase (125 days). The primary analysis involved a comparison of the proportion of patients experiencing clinical response, defined as at least a 100-point decrease in CDAI score from baseline at day 29. Data on adverse events were also collected. RESULTS: In all, 220 of the planned 282 patients were enrolled when the Data Monitoring Committee determined that the drug was not efficacious as a treatment and closed enrollment. A clinical response was experienced by 18 patients (24.7%) in the 50-mg daily (QD) group (n = 73) and 19 patients (25.7%) in the 100 mg QD group (n = 74), as compared with 21 patients (28.8%) in the placebo group (n = 73) on day 29 (P = 0.71 for each comparison). No significant adverse safety signal was observed. CONCLUSIONS: Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.